Shigemitsu Onizawa, Haruko Taniguchi, Tomoko Nozu, Asuka Asano, Hideki Katsura, Kumiko Saiki, Toshio Kiguchi, Mizue Hasegawa, Atsushi Nagai
Varenicline (Champix) is an alpha4beta2 nicotinic receptor antagonist that is used orally for treatment of nicotine dependence. We conducted a study to examine the sustainable efficacy of varenicline in smoking cessation. The subjects were 148 outpatients (113 men, 35 women; average age; 54.4 +/- 14.0 years) at 6 different hospitals, and their adverse events were monitored in each hospital. The 4-week continuous abstinence rates of smoking cessation were 17.6%, 75.0%, and 84.6% in groups treated for 4 or fewer weeks, 5 to 8 weeks, and 9 to 12 weeks, respectively, with the rate showing a significant increase according to treatment period...
November 2010: Nihon Kokyūki Gakkai Zasshi, the Journal of the Japanese Respiratory Society